Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514615 | 0.86 | PIK3R1 (0.41) | PIK3R1PIK3CACAMK2DNPSR1PLK1 | |
| SCHEMBL6522395 | 0.84 | PLK1 (0.45) | PIK3R1PIK3CACAMK2DPLK1ALDH1A1 | |
| SCHEMBL6506935 | 0.84 | PLK1 (0.44) | PIK3R1PIK3CACAMK2DPLK1 | |
| SCHEMBL6515579 | 0.80 | PIK3R1 (0.43) | PIK3R1PIK3CALMNAHTTNPSR1 | |
| SCHEMBL6521790 | 0.76 | FPR2 (0.42) | PIK3R1PIK3CAHTTPLK1KDM4E | |
| SCHEMBL6521909 | 0.75 | FEN1 (0.48) | PLK1ALDH1A1KDM4E | |
| SCHEMBL6522415 | 0.74 | CHEK1 (0.46) | PLK1 | |
| SCHEMBL6513337 | 0.73 | PIK3R1 (0.45) | PIK3R1PIK3CAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL6507966 | 0.73 | PIM1 (0.45) | CAMK2DALDH1A1 | |
| SCHEMBL6525512 | 0.73 | MAPT (0.51) | PIK3R1PIK3CALMNAHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | PIK3R1 439/4885PIK3CA 409/4885AAK1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.